BioSpace News Archive

Castor today announced the official launch of its CRO Partnership program.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA in oncogene amplified cancers, announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually.

Fabric Genomics, Inc., a leader in AI-based clinical decision support platforms for genomics-driven precision medicine, announced the appointment of Jyoti Palaniappan to its executive leadership team in the role of Chief Commercial Officer.

IVERIC bio, Inc. reported that on February 1, 2022, the Company granted an equity-based award pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee.

Concentric Analgesics, Inc today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.

CRISPR Therapeutics and ViaCyte, Inc., today announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210.

Evoke Pharma, Inc. and EVERSANA Life Science Services, today announced the extension of their agreement to continue collaborating on the commercialization and distribution of Gimoti ® (metoclopramide) nasal spray.

Juvena Therapeutics today announced that the company has been awarded a highly competitive translational grant from the California Institute of Regenerative Medicine (CIRM), totaling $3,906,376.

Bridge to Life Ltd. announced first enrollment and orthotopic liver transplantation in its U.S. pivotal Bridge to HOPE Liver Clinical Trial (NCT05045794).

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock.